A significant portion of advanced prostate cancer patients experience disease progression that remains invisible to standard blood tests, according to new research that could reshape how doctors monitor treatment effectiveness.

The findings, published in the Journal of Clinical Oncology by Armstrong and colleagues, emerge from a detailed reanalysis of two landmark phase III clinical trials—ARCHES and PROSPER—involving patients treated with enzalutamide, a widely-used hormonal therapy for advanced prostate disease.

The Silent Progression Problem

The research team discovered that radiographic progression—cancer advancement visible on imaging scans—frequently occurred without the telltale rise in prostate-specific antigen (PSA) levels that physicians have long relied upon as a warning signal. PSA blood tests have served as the workhorse of prostate cancer monitoring for decades, offering a simple, inexpensive way to track how patients respond to treatment.

But this post hoc analysis suggests that PSA levels don't always tell the complete story. In a substantial number of cases, tumors were advancing on CT scans and bone imaging while PSA markers remained deceptively stable or even declined.

The implications extend beyond academic interest. When disease progresses undetected, patients may continue ineffective treatments longer than necessary, potentially missing windows for alternative therapies that could extend survival or improve quality of life.

What the Trials Revealed

The ARCHES trial focused on metastatic hormone-sensitive prostate cancer—disease that has spread beyond the prostate but still responds to hormone-blocking treatments. PROSPER, meanwhile, examined non-metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy but hasn't yet shown distant spread on conventional imaging.

Together, these trials enrolled thousands of patients across multiple continents, making them among the most comprehensive investigations of enzalutamide's effectiveness. The original studies demonstrated clear benefits for the drug, leading to its widespread adoption in clinical practice.

Armstrong's team went back through this wealth of data with a specific question: How often does the cancer progress on scans before PSA levels signal trouble? The answer proved more common than many clinicians might expect.

Changing the Monitoring Playbook

The research doesn't suggest PSA testing has lost its value—far from it. PSA remains an important tool in the prostate cancer arsenal. But the findings argue for a more nuanced approach that combines blood work with periodic imaging, particularly for patients on enzalutamide and similar therapies.

"This challenges the practice pattern of relying primarily on PSA to guide treatment decisions," the researchers noted, according to reporting by The ASCO Post. The disconnect between biochemical markers and radiographic reality means some patients need scans even when their PSA numbers look reassuring.

For oncologists, this creates a balancing act. Imaging studies—CT scans and bone scans—cost more than blood tests, expose patients to radiation, and consume healthcare resources. Ordering them too frequently strains budgets and may detect insignificant changes. Ordering them too infrequently risks missing meaningful progression.

The Bigger Picture in Prostate Cancer Care

Prostate cancer remains the second-leading cause of cancer death among American men, with advanced disease presenting particularly difficult treatment challenges. Enzalutamide and related androgen receptor inhibitors have transformed outcomes for many patients, but resistance eventually develops in most cases.

Knowing precisely when resistance begins matters enormously. Early detection of progression allows physicians to switch strategies—perhaps moving to chemotherapy, trying newer agents, or enrolling patients in clinical trials of experimental treatments.

The post hoc nature of this analysis means it wasn't designed to answer every question. The researchers worked with existing trial data rather than prospectively testing a specific monitoring strategy. Still, the patterns proved consistent across two separate trials with different patient populations, lending credibility to the findings.

Future research will likely examine whether more intensive imaging surveillance actually improves patient outcomes, not just detection rates. After all, finding progression earlier only helps if doctors have effective next steps to offer.

For now, the message seems clear: in advanced prostate cancer, what you see on a scan and what you measure in blood don't always align. And when they diverge, the scan may be telling the more important story.